Skip to main content

Advertisement

SpringerLink
Log in

Nanocrystal for ocular drug delivery: hope or hype

  • Review Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

The complexity of the structure and nature of the eye emanates a challenge for drug delivery to formulation scientists. Lower bioavailability concern of conventional ocular formulation provokes the interest of researchers in the development of novel drug delivery system. Nanotechnology-based formulations have been extensively investigated and found propitious in improving bioavailability of drugs by overcoming ocular barriers prevailing in the eye. The advent of nanocrystals helped in combating the problem of poorly soluble drugs specifically for oral and parenteral drug delivery and led to development of various marketed products. Nanocrystal-based formulations explored for ocular drug delivery have been found successful in achieving increase in retention time, bioavailability, and permeability of drugs across the corneal and conjunctival epithelium. In this review, we have highlighted the ocular physiology and barriers in drug delivery. A comparative analysis of various nanotechnology-based ocular formulations is done with their pros and cons. Consideration is also given to various methods of preparation of nanocrystals with their patented technology. This article highlights the success achieved in conquering various challenges of ocular delivery by the use of nanocrystals while emphasizing on its advantages and application for ocular formulation. The perspectives of nanocrystals as an emerging flipside to explore the frontiers of ocular drug delivery are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18(5):290–7.

    Article  CAS  PubMed  Google Scholar 

  2. Conway BR. Recent patents on ocular drug delivery systems. Recent Pat Drug Deliv Formul. 2008;2(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  3. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine. 2009;5(4):394–401.

    PubMed  Google Scholar 

  4. Yang X, Trinh HM, Agrahari V, Sheng Y, Pal D, Mitra AK. Nanoparticle-based topical ophthalmic gel formulation for sustained release of hydrocortisone butyrate. AAPS PharmSciTech. 2015:1–13

  5. Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N. Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine. 2013;8:495–504.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197–216.

    Article  CAS  PubMed  Google Scholar 

  7. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13(3):135–43.

    PubMed  Google Scholar 

  8. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995;16(1):39–43.

    Article  CAS  Google Scholar 

  9. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599–617.

    Article  CAS  PubMed  Google Scholar 

  10. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002;28(4):353–69.

    Article  CAS  PubMed  Google Scholar 

  11. Prabhu P, Dubey A, Parth V, Ghate V. Investigation of hydrogel membranes containing combination of gentamicin and dexamethasone for ocular delivery. Int J Pharm Investig. 2015;5(4):214–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995;16(1):75–93.

    Article  CAS  Google Scholar 

  13. Abdelbary G, El-gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008;9(3):740–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15–34.

    Article  CAS  PubMed  Google Scholar 

  15. Kambhampati SP, Kannan RM. Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):151–65.

    Article  CAS  PubMed  Google Scholar 

  16. Barar I, Omidi Y. Nanoparticles for ocular drug delivery. Nanomedicine Drug Deliv. 2013;287.

  17. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev. 2008;60(15):1663–73.

    Article  CAS  PubMed  Google Scholar 

  18. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010;17(7):467–89.

    Article  CAS  PubMed  Google Scholar 

  19. Popov A, Enlow EM, Bourassa J, Gardner CR, Chen H, Ensign LM et al. Inventors; The Johns Hopkins University, assignee. Nanocrystals, compositions, and methods that aid particle transport in mucus. Baltimore, MD. US 9056057. 2013.

  20. Tuomela A, Liu P, Puranen J, Rönkkö S, Laaksonen T, Kalesnykas G, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014;467(1):34–41.

    Article  CAS  PubMed  Google Scholar 

  21. Reimondez-Troitiño S, Csaba N, Alonso M, de la Fuente M. Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharm. 2015;95:279–93.

  22. Holly FJ. Formation and stability of the tear film. Int Ophthalmol Clin. 1973;13(1):73–96.

    Article  CAS  PubMed  Google Scholar 

  23. Gunda S, Hariharan S, Mitra AK. Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. J Ocul Pharmacol Ther. 2006;22(6):465–76.

    Article  CAS  PubMed  Google Scholar 

  24. Grass GM, Robinson JR. Mechanisms of corneal drug penetration I: in vivo and in vitro kinetics. J Pharm Sci. 1988;77(1):3–14.

    Article  CAS  PubMed  Google Scholar 

  25. K-i H, Lee VH, Kim K-J. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm. 2005;60(2):227–40.

    Article  Google Scholar 

  26. Kim YC, Oh KH, Edelhauser HF, Prausnitz MR. Formulation to target delivery to the Ciliary body and choroid via the suprachoroidal space of the eye using microneedles. Eur J Pharm Biopharm. 2015;95:398–406.

  27. Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open ophthalmol J. 2010;4:52–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131–5.

    Article  CAS  PubMed  Google Scholar 

  29. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3):144–51.

    Article  CAS  PubMed  Google Scholar 

  31. Baeyens V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv. 1997;72(4):191–202.

    Article  CAS  PubMed  Google Scholar 

  32. Coursey TG, Henriksson JT, Marcano DC, Shin CS, Isenhart LC, Ahmad F, et al. Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release. 2015;213:168–74.

    Article  CAS  PubMed  Google Scholar 

  33. Bron A, Tiffany J, Gouveia S, Yokoi N, Voon L. Functional aspects of the tear film lipid layer. Exp Eye Res. 2004;78(3):347–60.

    Article  CAS  PubMed  Google Scholar 

  34. Ranta V-P, Mannermaa E, Lummepuro K, Subrizi A, Laukkanen A, Antopolsky M, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 2010;148(1):42–8.

    Article  CAS  PubMed  Google Scholar 

  35. Ye T, Yuan K, Zhang W, Song S, Chen F, Yang X, et al. Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery. Asian J Pharm Sci. 2013;8(4):207–17.

    Article  Google Scholar 

  36. X-j Y, Wang Y, Fu-Shin XY. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge. Invest Ophthalmol Vis Sci. 2000;41(13):4093–100.

    Google Scholar 

  37. Toda R, Kawazu K, Oyabu M, Miyazaki T, Kiuchi Y. Comparison of drug permeabilities across the blood–retinal barrier, blood–aqueous humor barrier, and blood–brain barrier. J Pharm Sci. 2011;100(9):3904–11.

    Article  CAS  PubMed  Google Scholar 

  38. Raviola G. The structural basis of the blood-ocular barriers. Exp Eye Res. 1977;25:27–63.

    Article  PubMed  Google Scholar 

  39. Cunha-Vaz J. The blood-retinal barriers. Doc Ophthalmol. 1976;41(2):287–327.

    Article  CAS  PubMed  Google Scholar 

  40. Khurana V, Patel SP, Agrahari V, Pal D, Mitra AK. Novel pentablock copolymer based nanoparticles containing pazopanib: a potential therapy for ocular neovascularization. Recent Pat Nanomedicine. 2014;4(1):57–68.

    Article  CAS  Google Scholar 

  41. Almazan A, Lee SS, Ross AD, Robinson MR. 7 Barriers to transscleral drug delivery to the retina. Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. 2012;133.

  42. Gaudana R, Barot M, Patel A, Khurana V, Mitra AK. Barriers for posterior segment ocular drug delivery. In: Mitra AK, editor. Treatise on Ocular Drug Delivery. Bentham E Books, 2013;68–95.

  43. Occhiutto ML, Freitas FR, Maranhao RC, Costa VP. Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems. Pharmaceutics. 2012;4(2):252–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pijls RT, Cruysberg LP, Nuijts RM, Dias AA, Koole LH. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm. 2007;341(1):152–61.

    Article  CAS  PubMed  Google Scholar 

  45. Fangueiro J, Veiga F, Silva A, Souto E. Ocular drug delivery-new strategies for targeting anterior and posterior segments of the eye. Curr Pharm Des. 2016;22(9):1135–46.

  46. Suresh PK, Sah AK. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. Expert Opin Drug Deliv. 2014;11(11):1747–68.

    Article  CAS  PubMed  Google Scholar 

  47. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 2001;33(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  48. Bourges J-L, Gautier SE, Delie F, Bejjani RA, Jeanny J-C, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562–9.

    Article  PubMed  Google Scholar 

  49. Dilnawaz F, Sahoo SK. Nanotechnology-based ophthalmic drug delivery system. Focal controlled drug delivery. Springer; 2014. p. 225–41.

  50. Diebold Y, Jarrín M, Saez V, Carvalho EL, Orea M, Calonge M, et al. Ocular drug delivery by liposome–chitosan nanoparticle complexes (LCS-NP). Biomaterials. 2007;28(8):1553–64.

    Article  CAS  PubMed  Google Scholar 

  51. Radomska-Soukharev A, Wojciechowska J. Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients. Acta Pol Pharm. 2005;62(6):465–71.

    CAS  PubMed  Google Scholar 

  52. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89–121.

    Article  CAS  PubMed  Google Scholar 

  53. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26(2):395–403.

    Article  CAS  PubMed  Google Scholar 

  54. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64(1):11–29.

    Article  CAS  PubMed  Google Scholar 

  55. Abdelkader H, Wu Z, Al-Kassas R, Alany RG. Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects. Int J Pharm. 2012;433(1):142–8.

    Article  CAS  PubMed  Google Scholar 

  56. Yavuz B, Bozdağ Pehlivan S, Ünlü N. Dendrimeric systems and their applications in ocular drug delivery. Sci World J. 2013;2013:1–13.

    Article  Google Scholar 

  57. Christie JG, Kompella UB. Ophthalmic light sensitive nanocarrier systems. Drug Discov Today. 2008;13(3):124–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112–20.

    Article  CAS  PubMed  Google Scholar 

  59. Katzer T, Chaves P, Bernardi A, Pohlmann A, Guterres SS, Ruver Beck RC. Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. J Microencapsul. 2014;31(6):519–28.

    Article  CAS  PubMed  Google Scholar 

  60. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 2003;255(1):13–32.

    Article  CAS  PubMed  Google Scholar 

  61. Patravale V, Kulkarni R. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827–40.

    Article  CAS  PubMed  Google Scholar 

  62. Malkani A, Date AA, Hegde D. Celecoxib nanosuspension: single-step fabrication using a modified nanoprecipitation method and in vivo evaluation. Drug Deliv Transl Res. 2014;4(4):365–76.

    Article  CAS  PubMed  Google Scholar 

  63. Shelar DB, Pawar SK, Vavia PR. Fabrication of isradipine nanosuspension by anti-solvent microprecipitation–high-pressure homogenization method for enhancing dissolution rate and oral bioavailability. Drug Deliv Transl Res. 2013;3(5):384–91.

    Article  CAS  PubMed  Google Scholar 

  64. Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10(1):13–23.

    Article  Google Scholar 

  65. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16(7):354–60.

    Article  CAS  PubMed  Google Scholar 

  66. Junghanns J-UA, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295–310.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm. 2013;453(1):142–56.

    Article  PubMed  Google Scholar 

  68. Sun B, Yeo Y. Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Curr Opin Solid State Mater Sci. 2012;16(6):295–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–96.

    Article  CAS  PubMed  Google Scholar 

  70. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62(1):3–16.

    Article  CAS  PubMed  Google Scholar 

  71. Gulsun T, Gursoy R, Levent O. Nanocrystal technology for oral delivery of poorly water soluble drugs. FARAD J Pharm Sci. 2009;34:55–65.

    CAS  Google Scholar 

  72. Shah T, Patel D, Hirani J, Amin A. Nanosuspensions as a drug delivery system: a comprehensive review. Drug Deliv Technol. 2007;7(9):42–52.

    CAS  Google Scholar 

  73. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427–40.

    Article  CAS  PubMed  Google Scholar 

  74. Sinha B, Müller RH, Möschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453(1):126–41.

    Article  CAS  PubMed  Google Scholar 

  75. de Waard H, Frijlink HW, Hinrichs WL. Bottom-up preparation techniques for nanocrystals of lipophilic drugs. Pharm Res. 2011;28(5):1220–3.

    Article  PubMed  Google Scholar 

  76. Chin WWL, Parmentier J, Widzinski M, Tan EH, Gokhale R. A brief literature and patent review of nanosuspensions to a final drug product. J Pharm Sci. 2014;103(10):2980–99.

    Article  CAS  PubMed  Google Scholar 

  77. Gadad A, Kumar SV, Dandagi P, Bolmol U, Pallavi NP. Nanoparticles and their therapeutic applications in pharmacy. Int J Pharm Sci Nanotechnol. 2014;7(3):2509–19.

    CAS  Google Scholar 

  78. Che E, Zheng X, Sun C, Chang D, Jiang T, Wang S. Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs. Asian J Pharm Sci. 2012;7(2):85–95.

    Google Scholar 

  79. Keck C. Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process. US 9040105. 2012.

  80. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals–special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78(1):1–9.

    Article  PubMed  Google Scholar 

  81. Petersen R. inventor Nanocrystals for use in topical cosmetic formulations and method of production thereof patent US 20100047297. 2010.

  82. Haynes DH. inventor Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs. US 5091188. 1992.

  83. Scholz P, Arntjen A, Müller RH, Keck CM. ARTcrystal® process for industrial nanocrystal production—optimization of the ART MICCRA pre-milling step. Int J Pharm. 2014;465(1):388–95.

    Article  CAS  PubMed  Google Scholar 

  84. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. inventors; Sterling Drug Inc., assignee. Surface modified drug nanoparticles. New York. US 5145684, 1992.

  85. Srivalli KMR, Mishra B. Drug nanocrystals: a way toward scale-up. Saudi Pharm J. 2014:1–19

  86. Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanoparticle Res. 2008;10(5):845–62.

    Article  CAS  Google Scholar 

  87. Krause K, Müller R. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int J Pharm. 2001;214(1):21–4.

    Article  CAS  PubMed  Google Scholar 

  88. Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1):129–39.

    Article  CAS  PubMed  Google Scholar 

  89. Baba K, Tanaka Y, Kubota A, Kasai H, Yokokura S, Nakanishi H, et al. A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolyzable dye. J Control Release. 2011;153(3):278–87.

    Article  CAS  PubMed  Google Scholar 

  90. Ali HS, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2011;149(2):175–81.

    Article  CAS  PubMed  Google Scholar 

  91. Kassem M, Rahman AA, Ghorab M, Ahmed M, Khalil R. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1):126–33.

    Article  CAS  PubMed  Google Scholar 

  92. Baba K, Nishida K. Steroid nanocrystals prepared using the nano spray dryer B-90. Pharmaceutics. 2013;5(1):107–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Gupta S, Samanta MK, Raichur AM. Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS PharmSciTech. 2010;11(1):322–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Nagai N, Yoshioka C, Mano Y, Tnabe W, Ito Y, Okamoto N, et al. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure. Exp Eye Res. 2015;132:115–23.

    Article  CAS  PubMed  Google Scholar 

  95. Nagai N, Ono H, Hashino M, Ito Y, Okamoto N, Shimomura Y. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles. J Oleo Sci. 2014;63(2):177–86.

    Article  CAS  PubMed  Google Scholar 

  96. Kim JH, Jang SW, Han SD, Hwang HD, Choi H-G. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods. Pharmazie. 2011;66(7):491–5.

    CAS  PubMed  Google Scholar 

  97. Schopf L, Enlow E, Popov A, Bourassa J, Chen H. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol Ther. 2014;3(1–2):63–72.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Baba K, Nishida K, Hashida N, inventors; Osaka University, assignee. Method for producing an aqueous dispersion of drug nanoparticles and use thereof. Osaka, US 20150087624, 2015.

  99. Sharma RK, Yassin AEB. Nanostructure-based platforms-current prospective in ophthalmic drug delivery. Indian J Ophthalmol. 2014;62(7):768–72.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release. 2014;183:51–66.

    Article  CAS  PubMed  Google Scholar 

  101. Müller RH, Shegokar R, Gohla S, Keck CM. Nanocrystals: production, cellular drug delivery, current and future products. Intracellular Delivery. Springer; 2011. pp. 411–32.

  102. Xu Q, Kambhampati SP, Kannan RM. Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol. 2013;20(1):26–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Ravichandran R. Nanoparticles in drug delivery: potential green nanobiomedicine applications. Int J Green Nanotechnol Biomed. 2009;1(2):B108–30.

    Google Scholar 

  104. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16(1):61–73.

    Article  CAS  Google Scholar 

  105. Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. Stability of nanosuspensions in drug delivery. J Control Release. 2013;172(3):1126–41.

    Article  CAS  PubMed  Google Scholar 

  106. Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 2011;406(1):145–52.

    Article  CAS  PubMed  Google Scholar 

  107. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409(1):260–8.

    Article  CAS  PubMed  Google Scholar 

  108. Kesisoglou F, Panmai S, Wu Y. Nanosizing—oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631–44.

    Article  CAS  PubMed  Google Scholar 

  109. Müller R, Keck C. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm. 2012;80(1):1–3.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Authors are also thankful to Prof. Anuradha K. Gajjar for her kind support in editing of manuscript.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, Nirma University, S. G. Highway, Ahmedabad, Gujarat, 382 481, India

    Om Prakash Sharma, Viral Patel & Tejal Mehta

Authors
  1. Om Prakash Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Viral Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tejal Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tejal Mehta.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, O.P., Patel, V. & Mehta, T. Nanocrystal for ocular drug delivery: hope or hype. Drug Deliv. and Transl. Res. 6, 399–413 (2016). https://doi.org/10.1007/s13346-016-0292-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-016-0292-0

Keywords

Search

Navigation